Combivent Respimat

Hyperkalemia, Acute Bronchitis, Pneumonia + 18 more

Treatment

9 FDA approvals

20 Active Studies for Combivent Respimat

What is Combivent Respimat

Salbutamol

The Generic name of this drug

Treatment Summary

Salbutamol is a medication that helps to open up the airways in people with asthma or COPD. It works by stimulating beta2-adrenergic receptors, which are located in the lungs, more than the beta1-adrenergic receptors in the heart. Salbutamol is a mixture of two isomers, R- and S-isomers, and the R-isomer has 150 times greater affinity for the beta2-receptor. A single R-isomer version of salbutamol, levalbuterol, was developed, but it is more expensive than salbutamol,

Proair HFA

is the brand name

image of different drug pills on a surface

Combivent Respimat Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Proair HFA

Salbutamol

1981

314

Approved as Treatment by the FDA

Salbutamol, also known as Proair HFA, is approved by the FDA for 9 uses like prophylaxis of Bronchospasm and prophylaxis of Exercise-induced bronchospasm .

prophylaxis of Bronchospasm

prophylaxis of Exercise-induced bronchospasm

Bronchospasm, Exercise-Induced

Bronchial Spasm

Asthma, Exercise-Induced

Chronic Obstructive Pulmonary Disease

Used to treat Chronic Obstructive Pulmonary Disease (COPD) in combination with Ipratropium

Bronchodilator Agents

Used to treat need of more than one bronchodilator in combination with Ipratropium

Exercise-Induced Bronchospasm

Bronchospasm

Effectiveness

How Combivent Respimat Affects Patients

Salbutamol (also known as albuterol) is a medicine used to open up airways and make breathing easier. It works by stimulating beta-1 and beta-2 receptors in the body, which can result in increased heart rate and relaxed muscles. Taking salbutamol can also cause changes in blood sugar and insulin levels. Additionally, it can cause potassium levels in the blood to drop. Levalbuterol is a related medication that contains only the R-enantiomer of salbutamol, and may have fewer side effects.

How Combivent Respimat works in the body

Salbutamol is a medication that relaxes the airways in the lungs. It works by activating beta2-adrenergic receptors, which then increases cyclic-3′,5′-adenosine monophosphate (cyclic AMP) levels. This increase in cyclic AMP leads to the relaxation of the smooth muscles in the airways, allowing air to flow more easily. Salbutamol also inhibits the release of mediators from mast cells in the airways. Compared to similar medications, salbutamol has fewer cardiovascular effects. When inhaled, salbutamol usually starts to work

When to interrupt dosage

The quantity of Combivent Respimat is contingent upon the diagnosed condition, like Bronchodilator Agents, Emphysema and Wheezing. The dosage fluctuates based on the method of delivery specified in the table below.

Condition

Dosage

Administration

Bronchitis, Chronic

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Respiratory (inhalation), Tablet, Tablet - Oral, Solution, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Liquid - Oral, Capsule, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Nasal, Inhalant - Nasal, Inhalant, Inhalant - Oral, Solution - Nasal, Aerosol, spray, Aerosol, spray - Oral, Solution - Intramuscular, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial

Bronchitis

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Respiratory (inhalation), Tablet, Tablet - Oral, Solution, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Liquid - Oral, Capsule, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Nasal, Inhalant - Nasal, Inhalant, Inhalant - Oral, Solution - Nasal, Aerosol, spray, Aerosol, spray - Oral, Solution - Intramuscular, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial

Asthma

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Respiratory (inhalation), Tablet, Tablet - Oral, Solution, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Liquid - Oral, Capsule, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Nasal, Inhalant - Nasal, Inhalant, Inhalant - Oral, Solution - Nasal, Aerosol, spray, Aerosol, spray - Oral, Solution - Intramuscular, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial

Acute Bronchitis

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Respiratory (inhalation), Tablet, Tablet - Oral, Solution, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Liquid - Oral, Capsule, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Nasal, Inhalant - Nasal, Inhalant, Inhalant - Oral, Solution - Nasal, Aerosol, spray, Aerosol, spray - Oral, Solution - Intramuscular, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial

Pneumonia

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Respiratory (inhalation), Tablet, Tablet - Oral, Solution, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Liquid - Oral, Capsule, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Nasal, Inhalant - Nasal, Inhalant, Inhalant - Oral, Solution - Nasal, Aerosol, spray, Aerosol, spray - Oral, Solution - Intramuscular, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial

Bronchial Spasm

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Respiratory (inhalation), Tablet, Tablet - Oral, Solution, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Liquid - Oral, Capsule, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Nasal, Inhalant - Nasal, Inhalant, Inhalant - Oral, Solution - Nasal, Aerosol, spray, Aerosol, spray - Oral, Solution - Intramuscular, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial

Asthma

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Respiratory (inhalation), Tablet, Tablet - Oral, Solution, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Liquid - Oral, Capsule, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Nasal, Inhalant - Nasal, Inhalant, Inhalant - Oral, Solution - Nasal, Aerosol, spray, Aerosol, spray - Oral, Solution - Intramuscular, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial

prophylaxis of Bronchospasm

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Respiratory (inhalation), Tablet, Tablet - Oral, Solution, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Liquid - Oral, Capsule, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Nasal, Inhalant - Nasal, Inhalant, Inhalant - Oral, Solution - Nasal, Aerosol, spray, Aerosol, spray - Oral, Solution - Intramuscular, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial

Emphysema

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Respiratory (inhalation), Tablet, Tablet - Oral, Solution, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Liquid - Oral, Capsule, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Nasal, Inhalant - Nasal, Inhalant, Inhalant - Oral, Solution - Nasal, Aerosol, spray, Aerosol, spray - Oral, Solution - Intramuscular, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial

Asthma

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Respiratory (inhalation), Tablet, Tablet - Oral, Solution, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Liquid - Oral, Capsule, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Nasal, Inhalant - Nasal, Inhalant, Inhalant - Oral, Solution - Nasal, Aerosol, spray, Aerosol, spray - Oral, Solution - Intramuscular, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial

Influenza

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Respiratory (inhalation), Tablet, Tablet - Oral, Solution, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Liquid - Oral, Capsule, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Nasal, Inhalant - Nasal, Inhalant, Inhalant - Oral, Solution - Nasal, Aerosol, spray, Aerosol, spray - Oral, Solution - Intramuscular, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial

Bronchodilation

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Respiratory (inhalation), Tablet, Tablet - Oral, Solution, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Liquid - Oral, Capsule, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Nasal, Inhalant - Nasal, Inhalant, Inhalant - Oral, Solution - Nasal, Aerosol, spray, Aerosol, spray - Oral, Solution - Intramuscular, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial

Airway secretion clearance therapy

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Respiratory (inhalation), Tablet, Tablet - Oral, Solution, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Liquid - Oral, Capsule, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Nasal, Inhalant - Nasal, Inhalant, Inhalant - Oral, Solution - Nasal, Aerosol, spray, Aerosol, spray - Oral, Solution - Intramuscular, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial

excess mucus or phlegm

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Respiratory (inhalation), Tablet, Tablet - Oral, Solution, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Liquid - Oral, Capsule, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Nasal, Inhalant - Nasal, Inhalant, Inhalant - Oral, Solution - Nasal, Aerosol, spray, Aerosol, spray - Oral, Solution - Intramuscular, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial

Bronchodilator Agents

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Respiratory (inhalation), Tablet, Tablet - Oral, Solution, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Liquid - Oral, Capsule, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Nasal, Inhalant - Nasal, Inhalant, Inhalant - Oral, Solution - Nasal, Aerosol, spray, Aerosol, spray - Oral, Solution - Intramuscular, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial

Hyperkalemia

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Respiratory (inhalation), Tablet, Tablet - Oral, Solution, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Liquid - Oral, Capsule, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Nasal, Inhalant - Nasal, Inhalant, Inhalant - Oral, Solution - Nasal, Aerosol, spray, Aerosol, spray - Oral, Solution - Intramuscular, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial

Respiratory Tract Infections

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Respiratory (inhalation), Tablet, Tablet - Oral, Solution, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Liquid - Oral, Capsule, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Nasal, Inhalant - Nasal, Inhalant, Inhalant - Oral, Solution - Nasal, Aerosol, spray, Aerosol, spray - Oral, Solution - Intramuscular, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial

Asthma, Exercise-Induced

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Respiratory (inhalation), Tablet, Tablet - Oral, Solution, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Liquid - Oral, Capsule, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Nasal, Inhalant - Nasal, Inhalant, Inhalant - Oral, Solution - Nasal, Aerosol, spray, Aerosol, spray - Oral, Solution - Intramuscular, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial

Bronchospasm, Exercise-Induced

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Respiratory (inhalation), Tablet, Tablet - Oral, Solution, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Liquid - Oral, Capsule, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Nasal, Inhalant - Nasal, Inhalant, Inhalant - Oral, Solution - Nasal, Aerosol, spray, Aerosol, spray - Oral, Solution - Intramuscular, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial

Chronic Obstructive Pulmonary Disease

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Respiratory (inhalation), Tablet, Tablet - Oral, Solution, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Liquid - Intramuscular, Intramuscular, Capsule - Respiratory (inhalation), Liquid - Oral, Capsule, Spray, metered, Spray, metered - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant - Respiratory (inhalation), Nasal, Inhalant - Nasal, Inhalant, Inhalant - Oral, Solution - Nasal, Aerosol, spray, Aerosol, spray - Oral, Solution - Intramuscular, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial

Warnings

There are 20 known major drug interactions with Combivent Respimat.

Common Combivent Respimat Drug Interactions

Drug Name

Risk Level

Description

Hydroxyzine

Major

The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Hydroxyzine.

Mobocertinib

Major

The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Mobocertinib.

Ziprasidone

Major

The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Ziprasidone.

1-benzylimidazole

Minor

The risk or severity of hypertension can be increased when Salbutamol is combined with 1-benzylimidazole.

2,5-Dimethoxy-4-ethylamphetamine

Minor

The risk or severity of hypertension can be increased when Salbutamol is combined with 2,5-Dimethoxy-4-ethylamphetamine.

Combivent Respimat Toxicity & Overdose Risk

Taking too much albuterol can cause side effects like rapid heart rate, high or low blood pressure, shaking, headache, dry mouth, nausea, dizziness, fatigue, trouble sleeping, and low potassium levels. Taking albuterol while pregnant may cause birth defects. Albuterol is not recommended for children under 4 years old. The most toxic dose of albuterol in mice has been determined to be 1100mg/kg.

image of a doctor in a lab doing drug, clinical research

Combivent Respimat Novel Uses: Which Conditions Have a Clinical Trial Featuring Combivent Respimat?

383 studies are currently in progress to assess the potential of Combivent Respimat to ameliorate Respiratory Tract Infections, Asthma and Chronic Obstructive Pulmonary Disease (COPD).

Condition

Clinical Trials

Trial Phases

Chronic Obstructive Pulmonary Disease

75 Actively Recruiting

Phase 3, Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 4

Bronchospasm, Exercise-Induced

0 Actively Recruiting

Asthma

90 Actively Recruiting

Phase 1, Phase 4, Early Phase 1, Phase 2, Not Applicable, Phase 3

prophylaxis of Bronchospasm

0 Actively Recruiting

Influenza

28 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Phase 1, Phase 3

Hyperkalemia

4 Actively Recruiting

Phase 3, Not Applicable, Phase 2, Phase 1

Bronchitis, Chronic

0 Actively Recruiting

excess mucus or phlegm

0 Actively Recruiting

Bronchodilator Agents

0 Actively Recruiting

Pneumonia

16 Actively Recruiting

Not Applicable, Early Phase 1, Phase 2

Bronchial Spasm

0 Actively Recruiting

Asthma

1 Actively Recruiting

Phase 2

Airway secretion clearance therapy

0 Actively Recruiting

Respiratory Sounds

5 Actively Recruiting

Phase 2, Phase 3

Asthma

1 Actively Recruiting

Phase 4

Asthma, Exercise-Induced

0 Actively Recruiting

Emphysema

4 Actively Recruiting

Phase 2, Not Applicable

Bronchitis

0 Actively Recruiting

Acute Bronchitis

8 Actively Recruiting

Phase 4, Not Applicable, Phase 3, Early Phase 1

Bronchodilation

0 Actively Recruiting

Combivent Respimat Reviews: What are patients saying about Combivent Respimat?

5

Patient Review

1/15/2020

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

I have two of these that I don't need anymore. If anyone in the Austin area is interested, please let me know.

5

Patient Review

1/15/2020

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

I have two brand new ones and one that's almost new. I don't need them anymore. If anybody is needing these, I'm willing to sale to try and get some of my money back 5126074137

5

Patient Review

4/6/2015

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

5

Patient Review

5/10/2015

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

5

Patient Review

4/6/2015

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

5

Patient Review

5/10/2015

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

4.3

Patient Review

7/18/2019

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

I switched to this inhaler a month ago, and I'm really pleased with it. It feels like it gives me more breath than my old one did, which is great now that I've quit smoking.

4.3

Patient Review

7/18/2019

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

I switched to this inhaler about a month ago, and I find that it gives me more breath than my previous inhaler.

4

Patient Review

3/10/2017

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

I wasn't thrilled with the design or performance of this product, but it did work half the time. The dosing was also inconsistent, which is frustrating. That said, I know people who have had success with this treatment, so maybe it's just me.

4

Patient Review

10/5/2019

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

This works better than my straight albuterol inhaler.

4

Patient Review

3/10/2017

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

This product is unfortunately ineffective much of the time, and when it does work, it doesn't deliver the full amount of medication. On top of that, it's expensive! I would not recommend this product to anyone.

4

Patient Review

10/5/2019

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

This works better than a traditional albuterol inhaler for me.

3.7

Patient Review

6/16/2018

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

I've been having issues with Combivent Respimat not lasting a full month, as it's only supposed to have 120 doses. In 2017, it averaged less than 25 days, and in May-June 2018, it barely lasted two weeks. I contacted the company but nothing changed.

3.7

Patient Review

6/16/2018

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

I have had continuing problems with Combivent Respimat. It is supposed to have 120 doses for the month but has typically not lasted a full month. Last year 2017 it averaged less than 25 days. For May and June of 2018 it barely lasts two weeks and I am left without medication for the remainder of the month. Something is wrong with this product.

3.3

Patient Review

11/21/2015

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

I wouldn't exactly call this an effective medication. It's tough to use and I cough as soon as I take it, so who knows how much of the dose I'm actually getting? If something isn't broken, there's no need to try and fix it.

3.3

Patient Review

11/21/2015

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

I was very disappointed with this product. It didn't work for me, was difficult to use, and made me cough. I don't understand why they felt the need to change a medication that wasn't broken in the first place.

2

Patient Review

10/4/2019

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

The price is very high.

2

Patient Review

7/16/2022

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

I've only just started using Combivent Respirtory, but my chest feels awful. It's like there's a fire inside. My bronchial tubes are really sore too. I'm 86 years old, and I hope there's something better out there for people in my situation.

2

Patient Review

7/16/2022

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

I recently started using Combivent Respiators and have not had a good experience so far. My chest feels like it's on fire, and my bronchial tubes are sore. I'm 86 years old, female, and I feel like there must be something better out there for me.

2

Patient Review

10/4/2019

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

The price is really high.

1.7

Patient Review

6/8/2015

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

The new inhaler is much more effective and easier to use. I don't have to lug around one of those tubes anymore.

1.7

Patient Review

6/8/2015

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

The new inhaler is much more effective, in my opinion. With the old one, I had to use a separate tube to make sure I got the full dose--which was inconvenient.

1.3

Patient Review

12/11/2020

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

I found this product to be ineffective. It didn't help me breathe any better, and I was actually winded from trying to use it. Definitely not worth your time or money.

1.3

Patient Review

4/21/2016

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

Though I need to take this more often for it to be effective, my doctor has advised against it.

1.3

Patient Review

12/11/2020

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

I found this treatment to be ineffective. It didn't help me breathe at all, and I was just as winded after using it.

1.3

Patient Review

4/21/2016

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

I would need to take this more often if it weren't for my doctor's advisement.

1

Patient Review

6/28/2018

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

I was given this medication by the VA a few months ago as a replacement for Atrovent, which is no longer available. I have found that since taking Combivent Respimat, I am more short winded than before. Additionally, I now have to do nebulizer treatments constantly. I would much rather take Atrovent back.

1

Patient Review

6/28/2018

Combivent Respimat for Bronchi Muscle Spasm resulting from COPD

I was on COPD inhalers since 2008 and they worked fine for me. Recently, the VA told me that Atrovent wasn't available anymore and gave me Combivent Respimat as a replacement. I have found that I am more short winded after taking it and constantly have to do nebulizer treatments now.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about combivent respimat

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is COMBIVENT RESPIMAT a rescue inhaler?

"Symbicort is also approved to treat asthma in adults and children ages 6 years and older. However, it is not meant to be used as a rescue medication for COPD for immediate breathing relief."

Answered by AI

Is combivent the same as albuterol?

"Combivent Respimat is used to treat chronic obstructive pulmonary disease (COPD). Albuterol sulfate is used to treat or prevent bronchospasm in people with reversible obstructive airway disease. Albuterol is also used as a preventative measure against exercise-induced bronchospasm."

Answered by AI

Is COMBIVENT RESPIMAT a steroid inhaler?

"No, Combivent Respimat (ipratropium / albuterol) is not a steroid. It contains two medications that help relax and open up the airways in your lungs. It works differently from steroids, which help to reduce inflammation (swelling) in the lungs."

Answered by AI

What is COMBIVENT RESPIMAT inhaler used for?

"This product is used to treat and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease, such as bronchitis and emphysema. This product contains 2 medications: ipratropium and albuterol (also known as salbutamol)."

Answered by AI

Clinical Trials for Combivent Respimat

Have you considered Combivent Respimat clinical trials?

We made a collection of clinical trials featuring Combivent Respimat, we think they might fit your search criteria.
Go to Trials
Image of National Institutes of Health Clinical Center in Bethesda, United States.

BPL-1357 for Flu

18 - 55
All Sexes
Bethesda, MD

Background: Influenza (flu) infections are a serious global health threat. Each year, between 3 and 5 million people get the flu, and up to 500,000 die from it. Current vaccines protect against seasonal flus, but broader vaccines are needed to protect against potential flu pandemics. Objective: To test an experimental flu vaccine. Eligibility: Healthy people aged 18 to 55 years. Design: The study will last 5 to 8 months and has 2 phases, A and B. The study vaccine will be given either as a shot in the arm or as a nasal spray. Participants will receive 1 of 3 combinations: (1) study vaccine in the nose and placebo in the arm; (2) placebo in the nose and study vaccine in the arm; or (3) placebo in the nose and placebo in the arm. A placebo is just like the real vaccine but contains no active ingredients. Phase A: Participants will have 5 clinic visits over 56 days. They will receive a shot and a nasal spray at 2 of the visits, 28 days apart. At each visit, they will have a physical exam, with tests of their blood, urine, and nasal secretions. They will check their temperature at home and record any symptoms for 7 days after each vaccine. Phase B: Participants will stay in the hospital for at least 9 days. They will be infected with a flu virus. They will provide blood, urine, and nasal fluid samples. They will have tests of their heart function. They will remain in the hospital until they test negative for the flu 2 days in a row. They will have 2 follow-up visits, 4 and 8 weeks after leaving the hospital.

Phase 2
Waitlist Available

National Institutes of Health Clinical Center (+1 Sites)

Luca T Giurgea, M.D.

Image of Vanderbilt University Medical Center in Nashville, United States.

High vs. Standard Dose Influenza Vaccines for Flu

18+
All Sexes
Nashville, TN

This will be a follow-up study to the "Comparison of High Dose vs. Standard Dose Influenza Vaccine in Lung Allograft Recipient" study (DMID Protocol Number 22-0014) at Vanderbilt University Medical Center. Lung transplantation is a life-saving therapy for patients with advanced lung disease, and is also associated with an improvement in quality of life. However, due to the need for life-long immunosuppression to prevent acute cellular rejection and chronic lung allograft dysfunction ("chronic rejection"), lung transplant recipients are at risk for developing major infections. In fact, one-year survival is 85%, with infection being the leading cause of death within the first year post-transplant. We will conduct a follow-up phase II, randomized, double-blind trial to assess the impact of subsequent administration of two doses of HD-IIV compared to two doses of SD-IIV among lung recipients during the early post-transplant period. Demonstration of improved immunogenicity from two doses of HD-IIV over consecutive influenza seasons would provide potential broad benefit in reducing influenza disease and its associated complications in lung transplant recipients. Moreover, studying vaccine immunogenicity and safety in the same participants over consecutive years can provide insight into the influence of immunosuppression levels and allograft aging on vaccine-mediated immune modulation. This proposed study design will contribute significantly to influenza vaccination guidance and policy for the highly vulnerable lung transplant population. This proposed study is designed to address several key knowledge gaps in vaccine-mediated protection of lung transplant recipients against influenza: * Is there increased immunogenicity with administration of one or two doses of HD-IIV or SD-IIV in the subsequent season compared to two doses of HD-IIV or SD-IIV in the first season? * What is the durability of the humoral and cellular immune response between influenza seasons and does two doses of HD-IIV or SD-IIV sustain higher HAI titers compared to two doses of HD-IIV or SD-IIV in the first season? * What is the impact of maintenance immunosuppression levels on influenza vaccine immunogenicity within the same participant? * Will the optimal immunogenic vaccination strategy be associated with an acceptable long-term safety profile over successive influenza seasons, including injection-site and systemic reactions, allosensitization, and organ rejection?

Phase 2
Recruiting

Vanderbilt University Medical Center

Natahsa Halasa, MD, MPH

Have you considered Combivent Respimat clinical trials?

We made a collection of clinical trials featuring Combivent Respimat, we think they might fit your search criteria.
Go to Trials
Image of Altasciences Inc - Kansas City in Overland Park, United States.

VNT-101 for Safety and Tolerability Study

18 - 59
All Sexes
Overland Park, KS

A randomized, double-blind, placebo-controlled Phase 1 study conducted at a single center with approximately 78 healthy adults aged 18-59 years. Part 1 Single Ascending Dose (SAD) will enroll 48 participants into six cohorts (S1-S6) to receive single oral doses of VNT-101 (100-1500 mg) or placebo under fasting or fed (S5 only) conditions. Part 2 Multiple Ascending Dose (MAD) will enroll 30 participants into three cohorts (M1-M3) to receive multiple oral doses of VNT-101 (250-750 mg BID Days 1-5, QD Day 6) or placebo under fasting conditions. Dose escalation in both parts will proceed after Protocol Safety Review Team (PSRT) review. The primary objective for Part 1 is to evaluate the safety and tolerability of single ascending oral (SAD) doses of VNT-101 in healthy adult participants under either fasting or fed conditions. The primary objective for part 2 is to evaluate the safety and tolerability of multiple ascending oral (MAD) doses of VNT-101 in healthy adult participants.

Phase 1
Recruiting

Altasciences Inc - Kansas City

Have you considered Combivent Respimat clinical trials?

We made a collection of clinical trials featuring Combivent Respimat, we think they might fit your search criteria.
Go to Trials